Could a common diabetes drug also fight gum disease?

NCT ID NCT07182123

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This pilot study will test whether a weekly injection of a GLP-1 receptor agonist (a type 2 diabetes drug) can improve gum health in 30 adults who have both periodontitis and diabetes. Researchers will measure changes in gum pocket depth, bleeding, and tooth mobility. The goal is to gather enough data to plan a larger, more definitive trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GLP-1 receptor agonist (a diabetes drug that may also reduce gum inflammation)

What this could lead to

If it works, this could point toward a new way to treat gum disease using existing diabetes medications.

What could go wrong

This is a very small pilot study with only 30 people, not yet recruiting. It is designed to gather data for a future trial, not to prove effectiveness. Results may not apply to everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic periodontitis diabetes mellitus periodontitis type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.